Since its approval, there have been no cases of torsades de pointes or unexplained sudden death among US patients treated with Caprelsa.

Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a ...

Viridian Therapeutics recently announced a royalty financing agreement with DRI Healthcare Trust, potentially unlocking up to US$300 million to support the commercial launch and development of ...

Buyout bosses intend to contest any attempt by competition watchdog to disqualify them as directors of British companies ...

Lucia Gray™, an Australian wellness accessories brand known for its design-led approach, has unveiled The Stylish Pill Box™ — a 7-day organizer that transforms medication and vitamin management into ...

Semaglutide 7 mg and 14 mg tablets are now available for reducing the risk of cardiovascular death, heart attack, or stroke ...

Taiwan’s Food and Drug Administration has initiated a recall of more than 1.12 million tablets of a thyroid medication ...

Police walk past a burned car used as a roadblock during a police operation against alleged drug traffickers in the Complexo ...

Some 77% of patients saw their tumours shrink, 8% saw them completely disappear, and 69% saw partial shrinkage of their ...

PFAS chemicals can stay in the body for years without breaking down. Now, a cholesterol medicine that has been around for ...

The Food and Drug Administration (FDA) has ordered the recall of two batches of a medication used to treat hypothyroidism, ...

BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG), which is impaired in LGMD and causes muscle wasting, initially in the ...